Home > Research > Publications & Outputs > Formulation of Antimicrobial Tobramycin Loaded ...

Research

Associated organisational unit

Electronic data

  • jfb-10-00026

    Final published version, 1.4 MB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

  • jfb-10-00026-Supplementary-Information

    Final published version, 620 KB, PDF document

    Available under license: CC BY: Creative Commons Attribution 4.0 International License

Links

Text available via DOI:

Keywords

View graph of relations

Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT. / Hill, Marcus; Cunningham, Richard; Hathout, Rania et al.
In: Journal of Functional Biomaterials, Vol. 10, No. 2, 26, 13.06.2019.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Hill, M, Cunningham, R, Hathout, R, Johnston, C, Hardy, J & Migaud, M 2019, 'Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT', Journal of Functional Biomaterials, vol. 10, no. 2, 26. https://doi.org/10.3390/jfb10020026

APA

Hill, M., Cunningham, R., Hathout, R., Johnston, C., Hardy, J., & Migaud, M. (2019). Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT. Journal of Functional Biomaterials, 10(2), Article 26. https://doi.org/10.3390/jfb10020026

Vancouver

Hill M, Cunningham R, Hathout R, Johnston C, Hardy J, Migaud M. Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT. Journal of Functional Biomaterials. 2019 Jun 13;10(2):26. doi: 10.3390/jfb10020026

Author

Hill, Marcus ; Cunningham, Richard ; Hathout, Rania et al. / Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT. In: Journal of Functional Biomaterials. 2019 ; Vol. 10, No. 2.

Bibtex

@article{dea5babbb5e44d03b7ac37edd8421966,
title = "Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT",
abstract = "Tobramycin is a potent antimicrobial aminoglycoside and its effective delivery by encapsulation within nanoparticle carriers could increase its activity against infections through a combination of sustained release and enhanced uptake. Effective antimicrobial therapy against a clinically relevant model bacteria (Pseudomonas aeruginosa) requires sufficient levels of therapeutic drug to maintain a drug concentration above the microbial inhibitory concentration (MIC) of the bacteria. Previous studies have shown that loading of aminoglycoside drugs in poly(lactic-co-glycolic) acid (PLGA)-based delivery systems is generally poor due to weak interactions between the drug and the polymer. The formation of complexes of tobramycin with dioctylsulfosuccinate (AOT) allows the effective loading of the drug in PLGA-nanoparticles and such nanoparticles can effectively deliver the antimicrobial aminoglycoside with retention of tobramycin antibacterial function. ",
keywords = "drug delivery, Formulation, pharmaceutical sciences, biomedical engineering",
author = "Marcus Hill and Richard Cunningham and Rania Hathout and Christopher Johnston and John Hardy and Marie Migaud",
year = "2019",
month = jun,
day = "13",
doi = "10.3390/jfb10020026",
language = "English",
volume = "10",
journal = "Journal of Functional Biomaterials",
issn = "2079-4983",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

RIS

TY - JOUR

T1 - Formulation of Antimicrobial Tobramycin Loaded PLGA Nanoparticles via Complexation with AOT

AU - Hill, Marcus

AU - Cunningham, Richard

AU - Hathout, Rania

AU - Johnston, Christopher

AU - Hardy, John

AU - Migaud, Marie

PY - 2019/6/13

Y1 - 2019/6/13

N2 - Tobramycin is a potent antimicrobial aminoglycoside and its effective delivery by encapsulation within nanoparticle carriers could increase its activity against infections through a combination of sustained release and enhanced uptake. Effective antimicrobial therapy against a clinically relevant model bacteria (Pseudomonas aeruginosa) requires sufficient levels of therapeutic drug to maintain a drug concentration above the microbial inhibitory concentration (MIC) of the bacteria. Previous studies have shown that loading of aminoglycoside drugs in poly(lactic-co-glycolic) acid (PLGA)-based delivery systems is generally poor due to weak interactions between the drug and the polymer. The formation of complexes of tobramycin with dioctylsulfosuccinate (AOT) allows the effective loading of the drug in PLGA-nanoparticles and such nanoparticles can effectively deliver the antimicrobial aminoglycoside with retention of tobramycin antibacterial function.

AB - Tobramycin is a potent antimicrobial aminoglycoside and its effective delivery by encapsulation within nanoparticle carriers could increase its activity against infections through a combination of sustained release and enhanced uptake. Effective antimicrobial therapy against a clinically relevant model bacteria (Pseudomonas aeruginosa) requires sufficient levels of therapeutic drug to maintain a drug concentration above the microbial inhibitory concentration (MIC) of the bacteria. Previous studies have shown that loading of aminoglycoside drugs in poly(lactic-co-glycolic) acid (PLGA)-based delivery systems is generally poor due to weak interactions between the drug and the polymer. The formation of complexes of tobramycin with dioctylsulfosuccinate (AOT) allows the effective loading of the drug in PLGA-nanoparticles and such nanoparticles can effectively deliver the antimicrobial aminoglycoside with retention of tobramycin antibacterial function.

KW - drug delivery

KW - Formulation

KW - pharmaceutical sciences

KW - biomedical engineering

U2 - 10.3390/jfb10020026

DO - 10.3390/jfb10020026

M3 - Journal article

VL - 10

JO - Journal of Functional Biomaterials

JF - Journal of Functional Biomaterials

SN - 2079-4983

IS - 2

M1 - 26

ER -